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Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a pleiotropic cytokine that controls the
production and function of blood cells, is dere-
gulated in clinical conditions such as rheumatoid
arthritis and leukemia, yet offers therapeutic value
for other diseases. Its receptors are heterodimers
consisting of a ligand-specific a subunit and a bc
subunit that is shared with the interleukin (IL)-3 and
IL-5 receptors. How signaling is initiated remains an
enigma. We report here the crystal structure of the
human GM-CSF/GM-CSF receptor ternary complex
and its assembly into an unexpected dodecamer or
higher-order complex. Importantly, mutagenesis of
the GM-CSF receptor at the dodecamer interface
and functional studies reveal that dodecamer forma-
tion is required for receptor activation and signaling.
This unusual form of receptor assembly likely applies
also to IL-3 and IL-5 receptors, providing a structural
basis for understanding their mechanism of activa-
tion and for the development of therapeutics.
INTRODUCTION
A common feature of cytokine receptor activation is ligand-
induced receptor aggregation involving the homo or heterodi-
merization of two or more receptor components and their
assembly into a fully functional signaling complex. Structural
data for heterodimeric receptor families that utilize a common
binding and signaling subunit such as the IL-2 and IL-6 re-
ceptor systems have provided unique insights into their func-
tional activation (Boulanger et al., 2003; Wang et al., 2005;496 Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc.Stauber et al., 2006). The GM-CSF, IL-3, and IL-5 family of
receptors remains the last major group of class I hemato-
poietic receptor systems to be structurally and functionally
elucidated.
The GM-CSF, IL-3, and IL-5 family of cytokines regulates the
survival, proliferation, differentiation, and functional activation
of hematopoietic cells (Guthridge et al., 1998) with GM-CSF
also controlling dendritic cell (Mellman and Steinman, 2001)
and T cell function (Barouch et al., 2002), thus linking innate
and acquired immunity. While on the one hand GM-CSF offers
therapeutic promise to bolster antitumor immunity (Sun et al.,
2002; Fleetwood et al., 2005) and innate immunity for the treat-
ment of Crohn’s disease (Korzenik et al., 2005), on the other
hand abnormalities in GM-CSF production or receptor function
have been implicated in multiple pathologies such as rheumatoid
arthritis (Cook et al., 2001), juvenile myelomonocytic leukemia
(Birnbaum et al., 2000), chronic myelomonocytic leukemia (Ram-
shaw et al., 2002), and alveolar proteinosis (Dirksen et al., 1998).
Furthermore, the GM-CSF receptor may also be important in the
pathogenesis of chronic myeloid leukemia and myeloprolifera-
tive diseases by propagating survival and proliferation signals
promoted by the abnormal expression of Bcr-Abl and JAK2
mutations, respectively (Wilson-Rawls et al., 1996; James et al.,
2005). The receptors for GM-CSF, IL-3, and IL-5 are expressed
at very low levels (100–1000 per cell) on the surface of hematopoi-
etic cells and comprise a cytokine-specific a subunit and the bc
subunit that is common to all three receptors (Guthridge et al.,
1998). Each a subunit binds cytokine with low affinity (KD = 0.2–
100 nM) but the presence of bc converts this to high affinity
(KD = 100 pM) causing dimerization of both subunits and receptor
activation (Stomski et al., 1996). Structure-function studies of
GM-CSF, IL-3, and IL-5 and their receptors have noted regions
of importance for ligand binding and biological activity; however
the composition, assembly, and underlying mechanisms of
receptor activation have remained elusive.
Figure 1. Structure of the GM-CSF Receptor Ternary Complex
GM-CSF is highlighted in blue and GMRa in yellow. One monomer of bc is shown in magenta (chain a) and the other in green (chain b). Labels correspond to
domain names. Orthogonal views show how the complex would sit on the membrane surface. The bottom panel shows the view of the receptor when looking
toward the membrane and the top panel shows a side-on view with the molecule sitting on a membrane surface. Observed N-linked carbohydrates are shown as
sticks. Disordered peptides that connect the C termini of each chain to the membrane are shown as dashed lines. This and the following figures were prepared
with PyMOL (DeLano, 2002).Although GM-CSF receptor activation follows general rules that
invoke receptor dimerization and tyrosine transphosphorylation
of the cytoplasmic domains (Schlessinger, 2000), it is not clear
how this is achieved. The GM-CSF receptor does not have intrin-
sic tyrosine kinase activity but associates with the tyrosine kinase
JAK2, which is required for bc transphosphorylation and the initi-
ation of signaling and biological activity. The cytoplasmic do-
mains of both GMRa and bc are essential for receptor activation
(Sakamaki et al., 1992; Muto et al., 1995), but it appears that
mainly bc associates with JAK2 (Brizzi et al., 1994; Quelle et al.,
1994; Lilly et al., 2001). Since the crystal structure of isolated bc
revealed a dimer in which the membrane-proximal domains
were 120 A˚ apart (Carr et al., 2001), a distance too great to allow
transphosphorylation of bc by their associated JAK2 kinases, it
has remained an enigma how activation of the GM-CSF, IL-3,and IL-5 family of receptors could be achieved. We show here
that the crystal structure of the GM-CSF ternary complex assem-
bles into an unexpected dodecamer arrangement. Functional
analyses show that this dodecamer or higher-order complex
brings two bc dimers into close proximity and provides for the
functional dimerization and activation of the GM-CSF receptor.
RESULTS
The Structure of the GM-CSF Receptor Complex
Reveals a Hexameric Assembly
We have determined the structure of the GM-CSF ternary com-
plex revealing a 2:2:2 hexamer consisting of two bc chains, two
GMRa chains, and two GM-CSF molecules (Figure 1). This dif-
fers from the 2:1:1 stoichiometry (2 bc: 1 GMRa: 1 GM-CSF)Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc. 497
we observed in solution (McClure et al., 2003). This is likely to be
a result of differences in the total protein concentration at which
the complex is formed as we observe a protein concentration-
dependent shift in molecular weight and hence stoichiometry
of GM-CSF receptor complex (Figure S1 and Table S2 available
online). The 2:1:1 complex probably represents a relatively sta-
ble intermediate in the assembly of higher-order 2:2:2 GM-CSF
receptor complexes. The structure adopted by GM-CSF in the
ternary complex appears very similar to the structure of the iso-
lated cytokine (Rozwarski et al., 1996). We also observe the
same intertwined bc homodimer previously seen in the structure
of the isolated bc subunit (Carr et al., 2001). In our case the dimer
is generated by a crystallographic two-fold axis that runs through
the center of the hexameric complex. A comparison of the bc
chain in the complex compared to the structure of the isolated
molecule (Carr et al., 2006) reveals that domain 4 has rotated
3 toward the crystallographic diad that runs through the center
of the hexameric complex (Figure S2). The hinge region about
which the rotation has occurred is located close to domain 1 in
the linker region connecting domains 3 and 4, although the
conformation of the linker region closely resembles that seen in
the isolated molecule. Each bc chain consists of two cytokine
receptor homology modules (CRMs), which in turn consist of
two fibronectin type III (FnIII) domains. The GMRa chain consists
of an N-terminal ‘‘knob’’ domain followed by one CRM. However,
we only observe good electron density for the C-terminal FnIII
domain of GMRa (GMRa domain 2). Although the electron
density for N-terminal FnIII domain (GMRa domain 1) is of poorer
quality, it was sufficient to recognize core b sheet enabling
a partial model to be built and refined.
GM-CSF Interactions with GMRa—Site 1
GM-CSF binds to the elbow region defined by domains 1 and 2
of GMRa, reminiscent of the binding mode seen in other class I
cytokine receptors (Wells and de Vos, 1996). There is a small
interaction surface between GM-CSF and GMRa domain 2 of
240 A˚2 per molecule with a surface complementarity of 0.66,
a value within the range of normal protein-protein interaction
surfaces (Figure 2, Site 1). Additional surface area would be pro-
vided by domain 1. The loop residues 241 to 251 and 299 to 305
of GMRa interact with residues 11 to 23 (helix A) and residues
112 to 118 (helix D) of the cytokine. This is consistent with muta-
genesis studies showing that D112 of GM-CSF interacts with
GMRa (Hercus et al., 1994b) and that GMRa residues Y248
and R302 are important for GM-CSF binding to GMRa (Rajotte
et al., 1997; Haman et al., 1999).
GM-CSF Interactions with bc—Site 2
Recruitment of bc to the GM-CSF:GMRa binary complex con-
verts the GM-CSF binding to high affinity and leads to receptor
activation (Hayashida et al., 1990; Bagley et al., 1997). Surpris-
ingly, our structure reveals a composite GM-CSF binding site
at the elbow region between domain 1 (A-B and E-F loops) of
one bc chain and domain 4 (B-C and F-G loops) of the second
bc chain (Figure 2, Site 2), an arrangement not seen previously
in cytokine-cytokine receptor complex structures (see Discus-
sion). The involvement of these loops in cytokine binding is
consistent with previous mutagenesis data (Lock et al., 1994;498 Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc.Woodcock et al., 1994, 1996; Murphy et al., 2003). The interac-
tion at Site 2 buries 570 A˚2 of surface area per molecule with
a surface complementarity value of 0.62. Helix A of GM-CSF
nestles into a surface crevice of bc formed by the E-F loop (res-
idues 100 to 107) of bc domain 1 and the B-C (residues 360 to
369) and F-G (residues 417 to 423) loops of domain 4 (Figure 2).
All the loops of bc that interact with cytokine adopt conforma-
tions very similar to that seen in isolated bc. In bc domain 1,
Y39 of the A-B loop forms pi-pi interactions with Y421 in the
F-G loop of domain 4. Residues V104, V105, and T106 of the
E-F loop of domain 1 nestle into a hydrophobic pocket formed
by helices A and C of GM-CSF. The side chain of the adjacent
F103 residue is sandwiched between E-F and A-B loops of
domain 1 stabilizing the conformation of this region in the Site
2 interface. D107 potentially forms a salt bridge interaction
with K72 of GM-CSF. Y365 and H367 of the B-C loop of domain
4 are positioned on either side of E21 of GM-CSF. In the F-G loop
of bc domain 4, Y421 hydrogen bonds with E21 of GM-CSF (Fig-
ure 2, Site 2). These observations are consistent with mutagen-
esis studies showing that the principal cytokine interaction with
bc occurs through a conserved glutamate in helix A of GM-
CSF (E21) (Lopez et al., 1992; Hercus et al., 1994a), IL-3 (E22)
(Barry et al., 1994), or IL-5 (E13) (Tavernier et al., 1995) with
E21 of GM-CSF making direct contact with bc (McClure et al.,
2003) and with alanine substitution of bc at Y39, F103, Y365,
H367, I368, or Y421 abolishing GM-CSF binding (Lock et al.,
1994; Woodcock et al., 1994, 1996; Murphy et al., 2003). Phenyl-
alanine substitution of Y421 ablates high-affinity binding of
GM-CSF and IL-3 (Figure S3), highlighting the importance of
the phenolic hydroxyl group in ligand binding.
Interactions between GMRa and bc—Site 3
Domain 2 of GMRa forms an extensive interaction with domain 4
of bc resulting in 680 A˚2 of buried surface area per molecule
with a surface complementary value of 0.52. The interface,
involving residues 231, 232, 259, 266–270, and 280–286 of
GMRa and residues 350, 353, 366–369, 389–400, and 418 of
bc, is predominantly hydrophobic with a rim of charged residues
(Figure 2, Site 3). We previously reported two surface hydropho-
bic patches, denoted H1 and H2, in our crystal structure of bc
domain 4 and speculated that they might be involved in interac-
tion with other parts of bc and GMRa, respectively (Rossjohn
et al., 2000). The structure reported here shows that residues
in H1 contact the A-B loop of bc domain 1 whereas residues of
H2, located at the edge of the beta strands D and E of bc domain
4, are involved in the formation of the interface with GMRa. The
Site 3 interface provides additional interacting surfaces between
GMRa and bc, thereby enhancing the overall binding affinity of
GM-CSF for its receptor.
The GM-CSF Receptor Complex Assembles
into a Dodecamer
The crystal lattice generates an unexpected dodecamer
complex, an assembly not previously observed in structures of
cytokine receptor complexes, consisting of two hexameric com-
plexes related by a crystallographic two-fold axis (Figure 3A).
Intriguingly, the dodecamer assembles in a head-to-head orien-
tation bringing the C-terminal tails of neighboring bc domain 40s
Figure 2. Peeled-away Interaction Surfaces between Components of the GM-CSF Receptor and Comparison of Related Class I Heteromeric
Cytokine Receptor Systems
(A) The surfaces are colored by residue property: blue is basic and red is acidic. Residues involved in the interfaces are labeled. The top panel shows how bc
interacts with GM-CSF (Site 2), the right middle panel shows the interaction between cytokine and GMRa (Site 1), and the bottom panel shows the interaction
surfaces between bc and GMRa (Site 3). The composite nature of the GM-CSF binding Site 2 surface of bc is highlighted by a cartoon of the bc:GM-CSF inter-
action shown to the left of the Site 2 surfaces. A detailed view of GM-CSF E21 and interacting residues of bc is shown to the right of the Site 2 surfaces.
(B) Ribbon representation of the GM-CSF receptor complex. The panel shows a blown-up view of part of the ternary complex in the same orientation presented in
the top panel of Figure 1. Also shown is the likely location of the GMRa knob domain.
(C) The IL-6 receptor complex (Boulanger et al., 2003). For clarity only the unique components of the hexameric complex are shown with the exception of the
second gp130 molecule where the N-terminal domain interacts with the cytokine molecule.
(D) The IL-2 receptor complex (Wang et al., 2005). Related receptor components in each of the three systems shown in (A)–(D) are highlighted by the same color.Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc. 499
Figure 3. The Dodecamer Complex
(A) View of the dodecamer when looking toward the membrane surface. Coloring as in Figure 1 with second hexamer in lighter shade. (A model of the complete
domain 1 of GMRa [labeled aD1] was superimposed onto the partial model derived from the crystallographic data.) Also shown is the likely location of the GMRa
knob domain. In the lower panel a simplified version of the upper panel highlights the arrangement of chains and domains. The chains of bc are labeled a to d and
domains denoted with a ‘‘D.’’
(B) Side-on (with respect to the membrane) view of the complex, highlighting peeled-away interaction surfaces between GMRa domain 2 and bc domain 4 of each
hexamer (Site 4).and GMRa domain 20s into close proximity, suggesting a physio-
logical relevance to the assembly (Figure 3B). The interaction
surface, that we term Site 4, is large with 770 A˚2 being buried
per hexamer with major contributions between bc domain 4 of
each hexamer (520 A˚2 per molecule) and the rest contributed
from an interaction between the GMRa of one hexamer and bc
domain 4 of the other. The mostly polar interface involves resi-
dues 260 and 261 of GMRa and residues 346–354, 357, 359,
362, and 430–435 of bc with a high surface complementarity
value of 0.63. The bc domain 4 dodecamer interface includes
the mutated N-linked glycosylation site, N346Q. Complex sugar
chains are readily accommodated at the interface with only the
first couple of sugars emanating from N346 located at the inter-
face while the rest protrude out into solution (Figure S4).500 Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc.Dodecamer Complex Provides a Mechanism
of Activation for JAK2 Associated with bc
The JAK/STAT pathway is the principal signal transduction path-
way used by cytokine receptors. JAK activation occurs by
ligand-induced dimerization and transphosphorylation of recep-
tor-bound JAK molecules that subsequently phosphorylate the
receptor itself, STATs, and other signaling molecules recruited
to the receptors (Rawlings et al., 2004). JAK2 activation is
a feature of GM-CSF receptor activation (Quelle et al., 1994;
Watanabe et al., 1996) and plays a critical and nonredundant
role in GM-CSF signaling (Watanabe et al., 1996; Parganas
et al., 1998). Although JAK2 has been seen to specifically asso-
ciate with bc (Brizzi et al., 1994; Soldi et al., 1997; Lilly et al., 2001)
its association with GMRa is much less clear (Quelle et al., 1994).
Figure 4. Association of JAK2 with bc but Not GMRa
(A) JAK2 does not associate with GMRa in the CTL-EN/IL3Ra/GMRa cell line. CTL-EN/IL3Ra/GMRawere lysed and immunoprecipitated with antibodies specific
for GMRa, for JAK2, or for an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2 or GMRa.
(B) JAK2 associates with bc but not GMRa in the CTL-EN/IL3Ra/GMRa/bc cell line. CTL-EN/IL3Ra/GMRa/bc were lysed and immunoprecipitated with antibodies
specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2.
(C) Phosphorylated JAK2 associates with bc but not GMRa in the hematopoietic cell line TF-1. TF-1 cells starved of GM-CSF for 18 hr were treated with 0 or
150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecip-
itates were analyzed by western blotting using antibodies specific for GMR, bc, or phosphorylated JAK2.
(D) JAK2 associates with bc but not GMRa in normal human monocytes and is phosphorylated only in the presence of GM-CSF. Cells were treated with 0 or
150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa or bc. Immunoprecipitates were analyzed by western blotting
using antibodies specific for GMRa, bc, total JAK2, and phosphorylated JAK2 (pJAK2).This is an important point as the selective association of JAK2
with bc would support the notion that juxtaposition of neighbor-
ing bc domain 40s as seen in the dodecamer complex (but not the
hexameric complex) (Figure 3B) would be required for JAK2
transphosphorylation and subsequent receptor activation.
First, we coimmunoprecipitated JAK2 with each receptor sub-
unit using CTL-EN cell lines stably expressing GMRa alone
(Figure 4A) or coexpressing GMRa and bc (Figure 4B) and ob-
served that only bc coimmunoprecipitated JAK2. Second, we
used the human erythroleukemic TF-1 cell line that endoge-
nously expresses both receptor subunits and proliferates in re-
sponse to GM-CSF to perform reverse experiments where
JAK2 immunoprecipitation brought down bc but not GMRa
(Figure 4C). Furthermore, following stimulation with GM-CSF,
immunoprecipitation of bc brought down GMRa as well as phos-
phorylated JAK2, indicating that the JAK2 preassociated with
bc only becomes phosphorylated after cytokine stimulation
(Figure 4C). Finally, we studied human monocytes, a key effector
cell type of the immune system and also observed JAK2 associ-
ation with bc but not with GMRa (Figure 4D). Association of JAK2
with bc was observed in the absence of GM-CSF stimulation,
and JAK2 binding and phosphorylation were upregulated follow-
ing GM-CSF treatment. Similar results were observed with cells
from a patient with acute myeloid leukemia and from purifiedhuman neutrophils (Figure S5). The exclusive association of
JAK2 with bc suggests that GMRa:bc heterodimerization is not
sufficient for receptor activation and that JAK2 activation by
GM-CSF requires functional bc dimerization as provided by the
dodecamer.
Interfering with Site 4 Profoundly Affects
Receptor Signaling
The dodecamer structure makes two important predictions that
have physiological consequences for how GM-CSF engages its
receptor and activates intracellular signaling. First, disruption of
the Site 4 interaction is predicted to disturb dodecamer assembly
and impede biological responses. Second, such disruption of
Site 4 interactions should have little impact on hexamer assembly
and so high-affinity binding should remain intact. We tested
these possibilities by first mutating specific bc residues in Site
4 that were identified in the structure to make contact between
hexamers. CTL-EN/IL3Ra/GMRa cells were stably transfected
with plasmids encoding wild-type or mutant bc (Figure 5A) and
then sorted for bc expression. The resulting stable pools
were assayed for GM-CSF- and IL-3-mediated proliferation
(Figure 5B). All cell lines showed an equivalent response to mu-
rine IL-2 (data not shown) that was used to normalize the prolifer-
ation responses. Mutation of residues 430–436 (M1) reducedCell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc. 501
proliferation in response to GM-CSF (50-fold) and IL-3 (450-fold).
Restoration of the buried tryptophan residue at 434 (M2)
increased GM-CSF and IL-3 function, suggesting that the
W434A substitution in M1 caused some degree of structural
perturbation contributing to the loss of function. Mutation of res-
idues 347–352, alone (M3) or combined with mutation of residues
354 and 362 (M5), had no effect on GM-CSF-mediated prolifera-
tion but caused a modest reduction in IL-3-mediated proliferation
(10-fold). Combination of M2 and M3 (M4) virtually abolished
proliferation in response to GM-CSF and IL-3, but additional mu-
tation of residues 354 and 362 (M6) partially restored GM-CSF
Figure 5. Mutation of bc at the Dodecamer
Interface Reduces GM-CSF- and IL-3-Medi-
ated Cell Proliferation and Signaling
(A) Dodecamer interface of one hexamer showing
Site 4 residues colored in orange, Site 3 residues
colored in gray, and the remaining residues col-
ored yellow for GMRa and magenta (domain 4a)
or green (domain 1d) for bc. The alanine substitu-
tions of Site 4 residues are listed under the figure
and some of the mutated residues are labeled.
(B) GM-CSF- and IL-3-mediated cell proliferation
is reduced by mutation of bc Site 4 contact resi-
dues. Proliferation of cells expressing wild-type
bc (filled circle), bcM1 (filled diamond), bcM2
(open diamond), bcM3 (open square), bcM4 (filled
square), bcM5 (open triangle), or bcM6 (filled trian-
gle) in response to GM-CSF (left panel) or IL-3
(right panel) was normalized against the prolifera-
tion of each cell line in response to murine IL-2.
Each point is determined in triplicate and error
bars represent one standard deviation. Represen-
tative data are shown from multiple experiments.
(C) GM-CSF- and IL-3-mediated cell signaling is
reduced by mutation of bc Site 4 contact residues.
CTL-EN/IL3Ra/GMRa cells expressing wild-type
bc or the bc M1, M4, or M6 mutants were stimu-
lated for 5 min with GM-CSF (upper panel) and
IL-3 (lower panel) at 0, 0.15, 1.5, 15, or 150 ng/ml.
Cells were lysed, immunoprecipitated with anti-
body specific for bc, then analyzed by western
blotting using an anti-phosphotyrosine antibody
(phos-Tyr) or an antibody specific for bc (Total
bc). Cell lysates were analyzed by western blotting
using antibodies specific for phosphorylated
JAK2 (phos-JAK2) or phosphorylated STAT5
(phos-STAT5).
and IL-3 function (Figure 5B). Importantly,
the strongest effect was observed with
M4 that encompassed both targeted
regions of the large area that forms Site
4 (Figure 5A). The IL-3 response is consis-
tently more sensitive to mutation of Site 4
residues in bc than the GM-CSF re-
sponse, but the overall hierarchy in mu-
tant function is conserved between the
two cytokines. CTL-EN cell lines express-
ing the bc mutants support high-affinity
binding sites for GM-CSF and IL-3 (Table
S3), indicating that functional bc Sites 2
and 3 are retained by these mutants and that they are expressed
on the cell surface. The reduced proliferation observed for cells
expressing bcM1, bcM4, and bcM6 was accompanied by
a greatly reduced ability of GM-CSF and IL-3 to stimulate tyrosine
phosphorylation of bc, JAK2, and STAT5 (Figure 5C) and a sub-
stantial loss of colony-forming capacity (bcM1) in bone marrow
cells stimulated with GM-CSF (Figure S6). Functional disruption
of Site 4 required multiple mutations, probably reflecting the large
surface area of this protein-protein interface. Together, these
data indicate that Site 4 residues predicted from the structure
to be essential for dodecamer formation affect GM-CSF receptor502 Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc.
Figure 6. Antibodies to bc Site 4 Inhibit
GM-CSF-Mediated Functions in Normal
Cells and in Leukemic Cells
(A) Affinity-purified antibodies to bc Site 4 residues
inhibit upregulation of CD11b in human neutro-
phils treated with GM-CSF. Histograms shows
relative fluorescence for CD11b staining on neu-
trophils either unstimulated (black) or GM-CSF-
stimulated in the presence of nil (red) or 4 mg/ml
(blue) of affinity-purified bc Site 4 antibody. Prein-
cubation with 1 mg/ml of an irrelevant control
antibody (dashed line) had no effect on CD11b
expression by unstimulated (black) or GM-CSF-
stimulated (red) neutrophils.
(B) Affinity-purified antibodies to bc Site 4 residues
inhibit GM-CSF-stimulated colony formation by
bone marrow cells from a patient with chronic
myelomonocytic leukemia (CMML). Bone marrow
mononuclear cells (13 105) from a patient with CMML were plated in 2 ng/ml GM-CSF plus medium (Nil), or plus 10 mg/ml bc Site 4 antibody (Site 4 Ab), or plus
0.5 mg/ml of a control bc antibody (Control Ab). Data show average of triplicate plates and error bars represent the standard error of the mean (SEM). The two-
tailed p value was generated using an unpaired t test.activation. Furthermore, our results show that high-affinity bind-
ing (and hexamer assembly) is not sufficient for biochemical or
functional receptor outputs and suggest that formation of
a higher-order dodecamer complex is an obligate step for full re-
ceptor activation.
To determine the physiological significance of the dodecamer
complex we generated antibodies specific to a portion of bc
(residues 427–440) within Site 4 and assessed their ability to in-
terfere with normal GM-CSF functions. Affinity-purified anti-
bodies against the bc Site 4 peptide recognized the immunizing
peptide as well as the soluble extracellular domains of bc
(Figure S7). We first examined GM-CSF upregulation of CD11b
in neutrophils, a key component of the CD11b/CD18 (Mac-1) in-
tegrin responsible for integrin activation, neutrophil adhesion,
leukocyte extravasation, and phagocytosis (Fagerholm et al.,
2006). Significantly, anti-bc Site 4 antibodies inhibited GM-
CSF-mediated upregulation of CD11b expression in human
neutrophils (Figure 6A). Furthermore, anti-bc Site 4 antibodies
inhibited GM-CSF-mediated colony formation from bone mar-
row cells of a patient with chronic myelomonocytic leukemia
(CMML), a condition where myeloid cells display a hypersensitive
response to GM-CSF (Figure 6B). These results indicate that
Site 4 is involved in normal as well as in immunopathological
functions mediated by GM-CSF.
DISCUSSION
We present here the structure of a ligand:receptor complex in the
GM-CSF/IL-3/IL-5 family of receptors and provide structural and
functional evidence for an unexpected form of cytokine receptor
assembly, namely a dodecamer, that can explain for the first time
how these receptors are activated. The structure of the GM-CSF
receptor complex reveals a hexamer with a stoichiometry of 2
GM-CSF:2 GMRa:2 bc, in an arrangement analogous to other
heteromeric cytokine receptors and using three sites of interac-
tion (Figure 2). Site 1 is formed largely by helix D of GM-CSF
interacting with domains 1 and 2 of GMRa. Site 2 is largely pro-
vided by helix A of GM-CSF interacting with a composite bc sur-
face comprising the A-B and E-F loops of domain 1 from one bcchain and the B-C and F-G loops of domain 4 of the second bc
chain. This elbow region resembles the ligand-binding interface
conserved in the simpler two-domain hematopoietin receptors,
despite domains 1 and 4 being noncontiguous. The composite
nature of the interface formed between GM-CSF and the bc di-
mer is highly unusual. In other ternary cytokine-cytokine receptor
complexes different regions of the cytokine interact with just one
receptor chain (Figure 2). More generally, we haven’t been able
to identify known examples of nonobligate heterotrimers that
involve an obligate dimer in which different surfaces of each
component interact with each other. The key to the Site 2 inter-
action is a hydrogen bond formed between E21 of GM-CSF and
Y421 in bc that is consistent with mutagenesis studies that
highlight the importance of these residues for GM-CSF binding
and function (Hercus et al., 1994a; Woodcock et al., 1996).
Mutagenesis studies suggest that structurally similar interac-
tions are likely to exist between Y421 of bc and E22 of IL-3 and
E13 of IL-5 (Barry et al., 1994; Tavernier et al., 1995: Woodcock
et al., 1996). Site 3 is formed between domain 2 of GMRa and
domain 4 of bc and serves to stabilize the cytokine-mediated
heterodimerization.
We observed a higher-order dodecamer complex composed
of two hexamers that interact through a Site 4 surface and bring
the membrane-proximal domains of bc and GMRa into close
proximity (Figure 3). The functional significance of the dodeca-
mer complex is supported first by the observation that JAK2,
which is essential for GM-CSF signaling, is associated with bc
and not GMRa (Figure 4). This could be seen in transfected cells,
in hemopoietic cell lines that respond to GM-CSF using endoge-
nous GM-CSF receptors, and, most importantly, in primary
human monocytes and neutrophils, essential leukocytes that
participate in immunity. Thus JAK2-associated bc as a homo-
dimer in the unliganded receptor (Muto et al., 1996; Stomski
et al., 1996; Carr et al., 2001) or as a heterodimer with GMRa in
the hexamer complex (Figure 1) would be too far apart (120 A˚)
to transphosphorylate the receptor. The dodecamer structure (Fig-
ure 3) on the other hand, brings JAK2-associated bc close enough
(10 A˚) to allow functional dimerization and transphosphorylation
of the receptor and initiation of signal transduction. Second,Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc. 503
Figure 7. Model of Signal Transduction
The low-affinity complex consists of GM-CSF bound to GMRa. Interaction with free bc forms the high-affinity hexamer complex. Dodecamer (or higher-order)
complexes form by lateral aggregation of hexamer complexes to form a fully competent signaling complex. JAK2 associated with bc (shown as red spheres) is
able to dimerize and transphosphorylate in the dodecamer complex but not in the hexamer complex.several mutants across the Site 4 interface decreased biological
activity and signaling with M4 showing an almost complete elim-
ination of function while not affecting high-affinity binding (Fig-
ure 5). Third, antibodies directed against part of bc Site 4 signif-
icantly reduced GM-CSF-mediated upregulation of the integrin
CD11b in human neutrophils and stimulation of the growth and
differentiation of leukemic cells (Figure 6).
Assembly of the dodecamer complex also promotes the inter-
action of two GMRa chains. While bc is the principal signaling
component of the GM-CSF/IL-3/IL-5 receptor family, it is clear
that the cytoplasmic domains of alpha chains are essential for
signal transduction (Muto et al., 1995; Lia et al., 1996; Lilly
et al., 2001). The observation that GMRa lacking a cytoplasmic
domain acts in a dominant-negative fashion (Lia et al., 1996)
indicates that the signaling complex must contain at least two
GMRa chains. In the dodecamer complex the GMRa cytoplas-
mic tails are 30 A˚ from the bc cytoplasmic tails of each neigh-
boring hexamer (Figure 3A), thus also providing a structural
explanation for how the cytoplasmic domain of GMRa can par-
ticipate in signaling.
In analyzing the role of Site 4 in receptor activation we focused
largely on two regions of bc, residues 344–365 and 427–438,
because their side chains are located in close proximity on the
surface of bc (Figure 5A). Interestingly, alanine substitution mu-
tants targeting only one of these regions at a time had little im-
pact on GM-CSF function (Figure 5B). The mutations with the
greatest effect on GM-CSF function, M4 and M6, encompassed
both regions of Site 4, suggesting that many residues in Site 4
contribute to the function of this interacting surface.
While we have not examined the effect of bc Site 4 mutations
on IL-5 function, the IL-5 dimer can be docked into our dodeca-
mer structure (Figure S8), suggesting that IL-5 is capable of
assembling a dodecamer complex. This particular assembly may
also allow the simultaneous incorporation of different cytokines
bound to the cognate alpha chain, potentially explaining how
stimulation of cells with IL-3 or IL-5 can result in phosphorylation
of the GM-CSF receptor (Woodcock et al., 1997). The structural
and functional data shown here support a model of GM-CSF/IL-
3/IL-5 receptor activation where the hexamer complex provides
for high-affinity cytokine binding but the dodecamer complex is504 Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc.required for receptor activation and signal transduction (Fig-
ure 7). Interestingly, the different mutations of bc at the Site 4
interface greatly reduced signaling and function not only from
GM-CSF but also from IL-3 (Figure 5), suggesting that dodeca-
mer formation may be a conserved mechanism utilized by the
whole GM-CSF/IL-3/IL-5 receptor family. As such it may offer
new avenues to interfere with receptor activation and facilitate
the development of new molecules, which by simultaneously
blocking GM-CSF, IL-3, and IL-5 function may be of clinical
use in diseases where all these cytokines play a pathogenic role.
EXPERIMENTAL PROCEDURES
Expression and Purification of Receptor Components
Soluble human GM-CSF was produced in Escherichia coli (Hercus et al.,
1994a). The soluble extracellular domains of GMRa or bc were expressed in
Sf21 insect cells and purified by affinity chromatography (McClure et al., 2003).
Structure Determination of the Complex
Ternary complex consisting of GM-CSF, sGMRa, and sbc was concentrated
to 5 mg/ml in 10 mM HEPES (pH 7.0). The best crystals were grown from a so-
lution containing 100 mM HEPES buffer (pH 7.0), 6% (v/v) PEG3350, 0.2 M pro-
line at 20C using the hanging drop technique. The crystals belonged to the
space group P6322 with unit cell dimensions a = b = 166.4 A˚ and c = 212.2 A˚.
Diffraction data were collected on the BioCARS beamline 14-BM-C at the
Advanced Photon Source (Chicago, IL, USA) (Table S1). The structure was de-
termined by molecular replacement using the known structure of isolated bc
(Carr et al., 2001) and refined at 3.3 A˚ resolution (Supplemental Data).
Mutagenesis and Generation of Cell Lines
Mutations of bc were generated by site-directed mutagenesis using the Al-
tered site system (Promega). Wild-type and Site 4 mutant bc cDNAs were
subcloned into the expression vector pRcCMVpuro (Woodcock et al., 1997).
Murine CTL-EN cells (Jenkins et al., 1999) stably expressing human IL3Ra
and GMRa chains (CTL-EN/IL3Ra/GMRa) were grown routinely in RPMI
1640 medium supplemented with 10% v/v FCS, 2 mM glutamine, 50 mM mer-
captoethanol, and 100 U/ml mIL-2. TF-1 cells were maintained as previously
described (Hercus et al., 1994a).
CTL-EN/IL3Ra/GMRa cells (5 3 106) were electroporated with 20 mg of
pRcCMVpuro DNA encoding wild-type or Site 4 mutant bc at 960 mF with
270 V and selected in 2–5 mg/ml puromycin 48 hr after transfection. Following
selection, pools of cells were sorted for bc expression by flow cytometry using
indirect immunofluorescence staining as previously described (Woodcock
et al., 1996) on a FACSAria (Becton Dickinson). Cells were starved of growth
factor overnight prior to use, and for biochemical studies, starve medium
included 0.5% v/v FCS.
Receptor Binding Assays
Radio-iodinated GM-CSF and IL-3 binding assays to CTL-EN/IL3Ra/GMRa
cell lines stably expressing wild-type bc or bc Site 4 mutants were as previously
described (Woodcock et al., 1994). COS cells were cotransfected with plas-
mids encoding GMRa and IL3Ra together with wild-type or bc Site 2 mutants
by electroporation and saturation binding assays with radio-iodinated cytokine
carried out in 24 well plates as previously described (Woodcock et al., 1996).
Dissociation constants were determined using Prism (Graphpad Software).
Cell Proliferation Assays
Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type bc or bc
Site 4 mutants were incubated (1 3 104 cells per well) with growth factors
over a range of concentrations for 40 hr. Cells were pulsed with 0.25 mCi/
well of [6-3H]-thymidine (GE-Healthcare) for 4 hr, harvested onto glass fiber fil-
ters, and counted in liquid scintillation fluid on a Top Count NXT (Perkin Elmer).
Immunoprecipitations and Immunoblotting
Human mononuclear cells from normal donors were isolated by Ficoll-Hypa-
que density-gradient centrifugation and resuspended in PBS containing
0.1% human albumin (CSL). CTL-EN/IL3Ra/GMRa and CTL-EN/IL3Ra/
GMRa/bc cells were lysed and immunoprecipitated using 4H1 anti-GMRa
monoclonal antibody (Stomski et al., 1998), 1C1 anti-bc monoclonal antibody
(Stomski et al., 1996), anti-JAK2 monoclonal antibody (Cell Signaling), or
12CA5 anti-influenza hemagglutinin monoclonal antibody. Samples from 2 3
107 cells were subjected to western blotting with antibodies specific for
GMRa or total JAK2. Human monocytes, starved TF-1 cells, or starved CTL-
EN/IL3Ra/GMRa/bc cells were stimulated with 0 or 150 ng/ml GM-CSF for
5 min, lysed, and immunoprecipitated using 4H1, 1C1, anti-JAK2, or 12CA5
monoclonal antibodies. Samples were subjected to western blotting with
antibodies specific for GMRa, bc, total JAK2, or tyrosine-phosphorylated
JAK2. Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type
bc or bc Site 4 mutants were stimulated with 0, 0.15, 1.5, 15, or 150 ng/ml
GM-CSF or IL-3 for 5 min, lysed, and immunoprecipitated using the 1C1
anti-bc monoclonal antibody. Samples of bc immunoprecipitates were sub-
jected to western blotting with 1C1 anti-bc or 4G10 anti-phosphotyrosine
monoclonal antibodies (Upsate Cell Signaling Solutions). Samples of cell ly-
sates were subjected to western blotting with antibodies specific for phos-
phorylated JAK2 or phosphorylated STAT5.
Generating and Functional Testing of Polyclonal Antibodies
against bc Site 4
Antibodies directed to bc Site 4 were generated by immunizing New Zealand
white rabbits with a peptide (EWSEARSWDTESVL) spanning residues 427–
440 of bc (Mimotopes) and conjugated to keyhole limpet antigen. Peptide-spe-
cific polyclonal antibody was affinity purified using the EWSEARSWDTESVL
peptide coupled to Sepharose. CD11b expression on neutrophils was moni-
tored as previously described (Guthridge et al., 2006) but included a 30 min
preincubation with antibody at 4C followed by a 30 min incubation with
15 ng/ml GM-CSF at 37C. The 12CA5 monoclonal antibody was used as
a negative control. Bone marrow colony assays where performed as previ-
ously described (Ramshaw et al., 2002) with the 1C1 monoclonal antibody
used as a negative control.
ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited in the Protein
Data Bank with accession code 3CXE.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight fig-
ures, and three tables and can be found with this article online at http://www.
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